Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Cell biology of pathogenic protozoa and their interaction with host cells.

Benchimol M, Engel JC, Tan KS, de Souza W.

Biomed Res Int. 2014;2014:143418. doi: 10.1155/2014/143418. Epub 2014 Jun 5. No abstract available.

2.

Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease.

Dandapani S, Germain AR, Jewett I, le Quement S, Marie JC, Muncipinto G, Duvall JR, Carmody LC, Perez JR, Engel JC, Gut J, Kellar D, Siqueira-Neto JL, McKerrow JH, Kaiser M, Rodriguez A, Palmer MA, Foley M, Schreiber SL, Munoz B.

ACS Med Chem Lett. 2013 Dec 29;5(2):149-53. doi: 10.1021/ml400403u. eCollection 2014 Feb 13.

3.

Identification of Diversity-Oriented Synthesis Derived Small Molecule, ML341, with Cidal Activity Against Trypanosoma cruzi.

Carmody LC, Germain AR, Engel JC, Gut J, Kaiser M, Jewett I, LeQuemen S, Marie JC, Dandapani S, Rodriguez A, Perez JR, McKerrow JH, Palmer MAJ, Munoz B, Schrieber SL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2013 Nov 7].

4.

Host metabolism regulates intracellular growth of Trypanosoma cruzi.

Caradonna KL, Engel JC, Jacobi D, Lee CH, Burleigh BA.

Cell Host Microbe. 2013 Jan 16;13(1):108-17. doi: 10.1016/j.chom.2012.11.011. Epub 2013 Jan 16.

5.

Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51.

Gunatilleke SS, Calvet CM, Johnston JB, Chen CK, Erenburg G, Gut J, Engel JC, Ang KK, Mulvaney J, Chen S, Arkin MR, McKerrow JH, Podust LM.

PLoS Negl Trop Dis. 2012;6(7):e1736. doi: 10.1371/journal.pntd.0001736. Epub 2012 Jul 31.

6.

The Trypanosoma cruzi protease cruzain mediates immune evasion.

Doyle PS, Zhou YM, Hsieh I, Greenbaum DC, McKerrow JH, Engel JC.

PLoS Pathog. 2011 Sep;7(9):e1002139. doi: 10.1371/journal.ppat.1002139. Epub 2011 Sep 1.

7.

A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit.

De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, McKerrow JH.

PLoS Negl Trop Dis. 2011 Jul;5(7):e1253. doi: 10.1371/journal.pntd.0001253. Epub 2011 Jul 19.

8.

Temporal analysis of the honey bee microbiome reveals four novel viruses and seasonal prevalence of known viruses, Nosema, and Crithidia.

Runckel C, Flenniken ML, Engel JC, Ruby JG, Ganem D, Andino R, DeRisi JL.

PLoS One. 2011;6(6):e20656. doi: 10.1371/journal.pone.0020656. Epub 2011 Jun 7.

9.

Mining a cathepsin inhibitor library for new antiparasitic drug leads.

Ang KK, Ratnam J, Gut J, Legac J, Hansell E, Mackey ZB, Skrzypczynska KM, Debnath A, Engel JC, Rosenthal PJ, McKerrow JH, Arkin MR, Renslo AR.

PLoS Negl Trop Dis. 2011 May 3;5(5):e1023. doi: 10.1371/journal.pntd.0001023.

10.

Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol.

Acharya P, Liao M, Engel JC, Correia MA.

J Biol Chem. 2011 Feb 4;286(5):3815-28. doi: 10.1074/jbc.M110.186981. Epub 2010 Nov 24.

11.
12.

Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Engel JC, Ang KK, Chen S, Arkin MR, McKerrow JH, Doyle PS.

Antimicrob Agents Chemother. 2010 Aug;54(8):3326-34. doi: 10.1128/AAC.01777-09. Epub 2010 Jun 14.

13.

A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SS, Jacobson MP, Engel JC, McKerrow JH, Podust LM.

Antimicrob Agents Chemother. 2010 Jun;54(6):2480-8. doi: 10.1128/AAC.00281-10. Epub 2010 Apr 12.

14.

Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.

Brak K, Kerr ID, Barrett KT, Fuchi N, Debnath M, Ang K, Engel JC, McKerrow JH, Doyle PS, Brinen LS, Ellman JA.

J Med Chem. 2010 Feb 25;53(4):1763-73. doi: 10.1021/jm901633v.

15.

Biolistic transformation of Schistosoma mansoni: Studies with modified reporter-gene constructs containing regulatory regions of protease genes.

Dvorák J, Beckmann S, Lim KC, Engel JC, Grevelding CG, McKerrow JH, Caffrey CR.

Mol Biochem Parasitol. 2010 Mar;170(1):37-40. doi: 10.1016/j.molbiopara.2009.11.001. Epub 2009 Nov 13.

PMID:
19914302
16.

Two approaches to discovering and developing new drugs for Chagas disease.

McKerrow JH, Doyle PS, Engel JC, Podust LM, Robertson SA, Ferreira R, Saxton T, Arkin M, Kerr ID, Brinen LS, Craik CS.

Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:263-9.

17.

A contiguous compartment functions as endoplasmic reticulum and endosome/lysosome in Giardia lamblia.

Abodeely M, DuBois KN, Hehl A, Stefanic S, Sajid M, DeSouza W, Attias M, Engel JC, Hsieh I, Fetter RD, McKerrow JH.

Eukaryot Cell. 2009 Nov;8(11):1665-76. doi: 10.1128/EC.00123-09. Epub 2009 Sep 11.

19.

Drugs targeting parasite lysosomes.

Doyle PS, Sajid M, O'Brien T, Dubois K, Engel JC, Mackey ZB, Reed S.

Curr Pharm Des. 2008;14(9):889-900. Review.

PMID:
18473838
20.

A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.

Doyle PS, Zhou YM, Engel JC, McKerrow JH.

Antimicrob Agents Chemother. 2007 Nov;51(11):3932-9. Epub 2007 Aug 13.

21.

Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii.

Que X, Engel JC, Ferguson D, Wunderlich A, Tomavo S, Reed SL.

J Biol Chem. 2007 Feb 16;282(7):4994-5003. Epub 2006 Dec 12.

22.

Giardia lamblia cysteine proteases.

DuBois KN, Abodeely M, Sajid M, Engel JC, McKerrow JH.

Parasitol Res. 2006 Sep;99(4):313-6. Epub 2006 Apr 6. Review. No abstract available.

PMID:
16598471
23.

Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.

Choe Y, Brinen LS, Price MS, Engel JC, Lange M, Grisostomi C, Weston SG, Pallai PV, Cheng H, Hardy LW, Hartsough DS, McMakin M, Tilton RF, Baldino CM, Craik CS.

Bioorg Med Chem. 2005 Mar 15;13(6):2141-56.

PMID:
15727867
24.
25.

Analysis of 6-(2,2-Dichloroacetamido)chrysene interaction with the hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi.

Medrano FJ, Wenck MA, Engel JC, Craig SP 3rd.

J Med Chem. 2003 Jun 5;46(12):2548-50.

PMID:
12773058
26.

Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.

Roush WR, Cheng J, Knapp-Reed B, Alvarez-Hernandez A, McKerrow JH, Hansell E, Engel JC.

Bioorg Med Chem Lett. 2001 Oct 22;11(20):2759-62.

PMID:
11591518
27.

Secretory and endocytic pathways converge in a dynamic endosomal system in a primitive protozoan.

Ghedin E, Debrabant A, Engel JC, Dwyer DM.

Traffic. 2001 Mar;2(3):175-88.

28.

Characterization of the Trypanosoma cruzi Cdc2p-related protein kinase 1 and identification of three novel associating cyclins.

Gómez EB, Santori MI, Laría S, Engel JC, Swindle J, Eisen H, Szankasi P, Téllez-Iñón MT.

Mol Biochem Parasitol. 2001 Mar;113(1):97-108.

PMID:
11254958
29.

Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi.

Freymann DM, Wenck MA, Engel JC, Feng J, Focia PJ, Eakin AE, Craig SP.

Chem Biol. 2000 Dec;7(12):957-68.

30.

Aryl ureas represent a new class of anti-trypanosomal agents.

Du X, Hansell E, Engel JC, Caffrey CR, Cohen FE, McKerrow JH.

Chem Biol. 2000 Sep;7(9):733-42.

31.

Trypanosoma cruzi: of man, kissing-bugs, and frogs.

Doyle PS, Hsieh I, Engel JC.

Exp Parasitol. 2000 May;95(1):71-4. No abstract available.

PMID:
10864520
32.

Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi.

Engel JC, Torres C, Hsieh I, Doyle PS, McKerrow JH.

J Cell Sci. 2000 Apr;113 ( Pt 8):1345-54. Erratum in: J Cell Sci 2000 Jul;113(Pt 14):2638. Garcia CT [corrected to Torres C].

33.

[Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease].

Engel JC, Doyle PS, McKerrow JH.

Medicina (B Aires). 1999;59 Suppl 2:171-5. Review. Spanish.

PMID:
10668260
34.

Cysteine protease inhibitors as chemotherapy: lessons from a parasite target.

Selzer PM, Pingel S, Hsieh I, Ugele B, Chan VJ, Engel JC, Bogyo M, Russell DG, Sakanari JA, McKerrow JH.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11015-22.

35.

Cysteine protease inhibitors as chemotherapy for parasitic infections.

McKerrow JH, Engel JC, Caffrey CR.

Bioorg Med Chem. 1999 Apr;7(4):639-44. Review.

PMID:
10353643
36.

Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif.

Huete-Pérez JA, Engel JC, Brinen LS, Mottram JC, McKerrow JH.

J Biol Chem. 1999 Jun 4;274(23):16249-56.

37.

A new member of YER057c family in Trypanosoma cruzi is adjacent to an ABC-transporter.

Robello C, Dallagiovanna B, Engel JC, Gamarro F, Castanys S.

Gene. 1998 Oct 5;220(1-2):1-12.

PMID:
9767076
38.

Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.

Engel JC, Doyle PS, Hsieh I, McKerrow JH.

J Exp Med. 1998 Aug 17;188(4):725-34.

39.

Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.

Engel JC, Doyle PS, Palmer J, Hsieh I, Bainton DF, McKerrow JH.

J Cell Sci. 1998 Mar;111 ( Pt 5):597-606.

40.

A primitive enzyme for a primitive cell: the protease required for excystation of Giardia.

Ward W, Alvarado L, Rawlings ND, Engel JC, Franklin C, McKerrow JH.

Cell. 1997 May 2;89(3):437-44.

41.

Leishmania major: comparison of the cathepsin L- and B-like cysteine protease genes with those of other trypanosomatids.

Sakanari JA, Nadler SA, Chan VJ, Engel JC, Leptak C, Bouvier J.

Exp Parasitol. 1997 Jan;85(1):63-76.

PMID:
9024203
42.

Cellular and molecular biological analyses of nifurtimox resistance in Trypanosoma cruzi.

Nozaki T, Engel JC, Dvorak JA.

Am J Trop Med Hyg. 1996 Jul;55(1):111-7.

PMID:
8702014
43.

The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design.

McKerrow JH, McGrath ME, Engel JC.

Parasitol Today. 1995 Aug;11(8):279-82.

PMID:
15275323
44.

The crystal structure of cruzain: a therapeutic target for Chagas' disease.

McGrath ME, Eakin AE, Engel JC, McKerrow JH, Craik CS, Fletterick RJ.

J Mol Biol. 1995 Mar 24;247(2):251-9.

PMID:
7707373
45.

Cloning of a virulence factor of Entamoeba histolytica. Pathogenic strains possess a unique cysteine proteinase gene.

Reed S, Bouvier J, Pollack AS, Engel JC, Brown M, Hirata K, Que X, Eakin A, Hagblom P, Gillin F, et al.

J Clin Invest. 1993 Apr;91(4):1532-40.

46.

Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi.

Harth G, Andrews N, Mills AA, Engel JC, Smith R, McKerrow JH.

Mol Biochem Parasitol. 1993 Mar;58(1):17-24.

PMID:
8459830
47.

A unique cysteine proteinase gene of pathogenic Entamoeba histolytica correlates with virulence.

Reed S, Bouvier J, Hirata K, Que X, Pollack AS, Engel JC, Gillin F, McKerrow JH.

Arch Med Res. 1992;23(2):181-2.

PMID:
1340288
48.

Leishmania donovani: long-term culture of axenic amastigotes at 37 degrees C.

Doyle PS, Engel JC, Pimenta PF, da Silva PP, Dwyer DM.

Exp Parasitol. 1991 Oct;73(3):326-34.

PMID:
1915747
49.

Isolate-dependent differences in the oxidative metabolism of Trypanosoma cruzi epimastigotes.

Engel JC, Doyle PS, Dvorak JA.

Mol Biochem Parasitol. 1990 Feb;39(1):69-76.

PMID:
2406595
50.

Leishmania mexicana mexicana: quantitative analysis of the intracellular cycle.

Doyle PS, Engel JC, Gam AA, Dvorak JA.

Parasitology. 1989 Dec;99 Pt 3:311-6.

PMID:
2608309

Supplemental Content

Loading ...
Support Center